DK1608753T3 - Antisens-oligonukleotider (ODN) mod Smad7 og anvendelser deraf i det medicinske felt - Google Patents

Antisens-oligonukleotider (ODN) mod Smad7 og anvendelser deraf i det medicinske felt

Info

Publication number
DK1608753T3
DK1608753T3 DK04718384T DK04718384T DK1608753T3 DK 1608753 T3 DK1608753 T3 DK 1608753T3 DK 04718384 T DK04718384 T DK 04718384T DK 04718384 T DK04718384 T DK 04718384T DK 1608753 T3 DK1608753 T3 DK 1608753T3
Authority
DK
Denmark
Prior art keywords
odn
medical field
applications
antisense oligonucleotides
against smad7
Prior art date
Application number
DK04718384T
Other languages
Danish (da)
English (en)
Inventor
Giovanni Monteleone
Original Assignee
Giuliani Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Giuliani Int Ltd filed Critical Giuliani Int Ltd
Application granted granted Critical
Publication of DK1608753T3 publication Critical patent/DK1608753T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK04718384T 2003-04-02 2004-03-08 Antisens-oligonukleotider (ODN) mod Smad7 og anvendelser deraf i det medicinske felt DK1608753T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2003RM000149 ITRM20030149A1 (it) 2003-04-02 2003-04-02 Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
PCT/IT2004/000117 WO2004087920A1 (en) 2003-04-02 2004-03-08 Antisense oligonucleotides (odn) against smad7 and uses in medical field thereof

Publications (1)

Publication Number Publication Date
DK1608753T3 true DK1608753T3 (da) 2009-04-14

Family

ID=29765741

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04718384T DK1608753T3 (da) 2003-04-02 2004-03-08 Antisens-oligonukleotider (ODN) mod Smad7 og anvendelser deraf i det medicinske felt

Country Status (21)

Country Link
US (18) US7700757B2 (no)
EP (1) EP1608753B1 (no)
JP (2) JP4559411B2 (no)
KR (1) KR100822972B1 (no)
CN (1) CN100556461C (no)
AT (1) ATE417102T1 (no)
AU (1) AU2004225666B2 (no)
CA (1) CA2520541C (no)
CY (1) CY1108870T1 (no)
DE (1) DE602004018288D1 (no)
DK (1) DK1608753T3 (no)
ES (1) ES2316970T3 (no)
IT (1) ITRM20030149A1 (no)
MX (1) MXPA05010549A (no)
NO (1) NO334022B1 (no)
NZ (1) NZ542718A (no)
PL (1) PL1608753T3 (no)
PT (1) PT1608753E (no)
RU (1) RU2339697C2 (no)
SI (1) SI1608753T1 (no)
WO (1) WO2004087920A1 (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700572B2 (en) * 2001-11-02 2010-04-20 Giuliani International, Ltd. SMAD7 inhibitors for the treatment of CNS diseases
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
AU2009315898B2 (en) * 2008-11-13 2015-07-23 Nogra Pharma Limited Antisense compositions and methods of making and using same
KR101881596B1 (ko) 2008-12-02 2018-07-24 웨이브 라이프 사이언시스 재팬 인코포레이티드 인 원자 변형된 핵산의 합성 방법
CN102596204B (zh) 2009-07-06 2016-11-23 波涛生命科学有限公司 新的核酸前药及其使用方法
WO2012039448A1 (ja) 2010-09-24 2012-03-29 株式会社キラルジェン 不斉補助基
CA2815212A1 (en) * 2010-10-22 2012-04-26 Curna, Inc. Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
ES2626488T3 (es) 2011-07-19 2017-07-25 Wave Life Sciences Pte. Ltd. Procedimientos para la síntesis de ácidos nucleicos funcionalizados
ES2617200T3 (es) 2011-09-15 2017-06-15 Nogra Pharma Limited Procedimientos para supervisar la capacidad de respuesta al tratamiento anti-SMAD7
CA2870547A1 (en) * 2012-04-18 2013-10-24 Nogra Pharma Limited Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation
SG11201500232UA (en) 2012-07-13 2015-04-29 Wave Life Sciences Pte Ltd Chiral control
EP2873674B1 (en) 2012-07-13 2020-05-06 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
AU2013288048A1 (en) 2012-07-13 2015-01-22 Wave Life Sciences Ltd. Asymmetric auxiliary group
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
ES2673209T3 (es) * 2013-03-15 2018-06-20 Nogra Pharma Limited Procedimientos de tratamiento del cáncer colorrectal
WO2014198890A1 (en) * 2013-06-13 2014-12-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of erythropoietic protoporphyria
EP3095461A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
EP3095459A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
CN106068325B (zh) 2014-01-16 2021-07-09 波涛生命科学有限公司 手性设计
WO2015169966A2 (en) * 2014-05-09 2015-11-12 Nogra Pharma Limited Methods for treating inflammatory bowel disease
US10570169B2 (en) 2014-05-22 2020-02-25 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
WO2015011694A2 (en) 2014-10-17 2015-01-29 Celgene Corporation Isotopologues of smad7 antisense oligonucleotides
JP2017537973A (ja) * 2014-10-17 2017-12-21 ノグラ ファーマ リミテッド バイオマーカーレベルを使用してｓｍａｄ７アンチセンスオリゴヌクレオチドを投与するおよびモニタリングするための方法
WO2016059239A1 (en) * 2014-10-17 2016-04-21 Nogra Pharma Limited Methods and compositions for treating a subject with a smad7 antisense oligonucleotide
MA41271A (fr) * 2014-12-26 2017-10-31 Celgene Alpine Invest Company Ii Llc Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7
WO2016130832A1 (en) 2015-02-13 2016-08-18 Idera Pharmaceuticals, Inc. Toll-like receptor 9 antagonist and methods of use thereof
WO2016196897A1 (en) 2015-06-04 2016-12-08 Sarepta Therapeutics, Inc. Methods and compounds for treatment of lymphocyte-related diseases and conditions
EP3316894A4 (en) 2015-07-02 2019-06-19 City of Hope COMPOUNDS AND COMPOSITIONS USING PHOSPHOROIDED OLIGODESOXYNUCLEOTIDE AND METHOD OF USE THEREOF
EP3356530A4 (en) * 2015-09-30 2019-04-10 Celgene Alpine Investment Company II, LLC TLR MODULATORS AND ASSOCIATED METHODS OF USE
US11162097B2 (en) 2016-02-23 2021-11-02 Nogra Pharma Limited Methods of treating intestinal fibrosis using SMAD7 inhibition
US11134889B2 (en) * 2016-12-14 2021-10-05 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a SMAD7 inhibitor
WO2019051173A1 (en) 2017-09-08 2019-03-14 Ionis Pharmaceuticals, Inc. MODULATORS OF SMAD7 EXPRESSION
US20200332302A1 (en) * 2017-12-30 2020-10-22 The Regents Of The University Of Colorado, A Body Corporate Therapeutics of ptd-smad7 fusion proteins
US10768615B2 (en) * 2018-02-26 2020-09-08 Sanskar Agrawal System and method for automated hospital beds

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096722A (en) * 1990-08-14 2000-08-01 Isis Pharmaceuticals Inc. Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
AU678769B2 (en) * 1992-07-27 1997-06-12 Hybridon, Inc. Oligonucleotide alkylphosphonothioates
US6884787B2 (en) * 2001-07-14 2005-04-26 Isis Pharmaceuticals, Inc. Antisense modulation of transforming growth factor-beta 3 expression
US5654004A (en) * 1992-11-06 1997-08-05 Hisamitsu Pharmaceutical Co., Inc. Oral pharmaceutical preparation releasable in the lower digestive tract
US20020177568A1 (en) * 1992-12-07 2002-11-28 Stinchcomb Dan T. Enzymatic nucleic acid treatment of diseases or conditions related to levels of NF-kappa B
DE69432375T2 (de) * 1993-04-30 2004-02-12 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH Antisense Oligonukleotide zur Behandlung von immunsuppressiven Wirkungen von TGF-beta2
GB9516268D0 (en) * 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
US6099823A (en) 1996-02-16 2000-08-08 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of cardiovascular disease
AU725192B2 (en) 1996-02-16 2000-10-05 Brigham And Women's Hospital Compositions and methods for the treatment and diagnosis of cardiovascular disease
US5783566A (en) * 1996-05-10 1998-07-21 California Institute Of Technology Method for increasing or decreasing transfection efficiency
US5856462A (en) * 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
JPH10295381A (ja) * 1997-04-23 1998-11-10 Seibutsu Bunshi Kogaku Kenkyusho:Kk 新規シグナル伝達因子、およびそれをコードする遺伝子
JP3431637B2 (ja) 1997-05-20 2003-07-28 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Ｓｍａｄ７およびその使用
JP2002510319A (ja) * 1997-07-01 2002-04-02 アイシス・ファーマシューティカルス・インコーポレーテッド オリゴヌクレオチドの消化管を介したデリバリーのための組成物及び方法
US5874416A (en) * 1997-11-07 1999-02-23 Sheikhnejad; Gholamreza RAS antisense inhibition
JP2002509711A (ja) 1998-03-27 2002-04-02 イーライ・リリー・アンド・カンパニー 血管疾患の処置および阻止
JPH11335269A (ja) * 1998-05-19 1999-12-07 Hisamitsu Pharmaceut Co Inc 遺伝子関連医薬の経口投与固形製剤
EP1469009A2 (en) 1998-05-21 2004-10-20 Isis Parmaceuticals, Inc. Compositions and methods for non-parenteral delivery of oligonucleotides
US6228642B1 (en) 1998-10-05 2001-05-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression
US5962673A (en) 1998-11-20 1999-10-05 Isis Pharmaceuticals Inc. Antisense modulation of inhibitor-kappa B kinase-alpha expression
US6479465B2 (en) * 1999-03-24 2002-11-12 The United States Of America As Represented By The Department Of Health And Human Services Methods of treating colitis using STAT-4 anti-sense oligonucleotides
US6159697A (en) 2000-01-19 2000-12-12 Isis Pharmaceuticals, Inc. Antisense modulation of Smad7 expression
US20020147140A1 (en) * 2000-01-31 2002-10-10 Rosen Craig A. Nucleic acids, proteins, and antibodies
CA2392757A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences Inc. Nucleic acids, proteins, and antibodies
WO2001062207A2 (en) * 2000-02-23 2001-08-30 The Regents Of The University Of California Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
US20020061569A1 (en) * 2000-03-21 2002-05-23 Robert Haselbeck Identification of essential genes in prokaryotes
WO2001094629A2 (en) 2000-06-05 2001-12-13 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets
EP1294947A2 (en) 2000-06-30 2003-03-26 Epigenomics AG Method and nucleic acids for pharmacogenomic methylation analysis
US20030134324A1 (en) 2000-08-07 2003-07-17 Munger William E. Identifying drugs for and diagnosis of Benign Prostatic Hyperplasia using gene expression profiles
WO2002068579A2 (en) 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
AU2002306849A1 (en) 2001-03-21 2002-10-08 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
WO2002085285A2 (en) 2001-04-18 2002-10-31 Wyeth Methods and reagents for regulating bone and cartilage formation
AUPR638101A0 (en) * 2001-07-13 2001-08-09 Bioa Pty Limited Composition and method for treatment of disease
US7700572B2 (en) * 2001-11-02 2010-04-20 Giuliani International, Ltd. SMAD7 inhibitors for the treatment of CNS diseases
EP1308459A3 (en) 2001-11-05 2003-07-09 Research Association for Biotechnology Full-length cDNA sequences
JP2003135075A (ja) * 2001-11-05 2003-05-13 Research Association For Biotechnology 新規な全長ｃＤＮＡ
US20060263774A1 (en) 2002-11-01 2006-11-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
AU2003296944A1 (en) 2002-12-10 2004-06-30 George Koob A method for treatment of drug addiction and for screening of pharmaceutical agents therefor
WO2004083389A2 (en) 2003-03-13 2004-09-30 Exelixis Inc. Mbcats as modifiers of the beta-catenin pathway and methods of use
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
US20040265833A1 (en) * 2003-06-23 2004-12-30 Cathy Lofton-Day Methods and nucleic acids for the analysis of colorectal cell proliferative disorders
AU2004262369A1 (en) 2003-07-29 2005-02-10 Bristol-Myers Squibb Company Biomarkers of cyclin-dependent kinase modulation
ITRM20030393A1 (it) 2003-08-11 2005-02-12 Giuliani Spa Uso di oligonucleotidi (odn) antisenso per smad7 per il trattamento delle patologie mediate dal fattore di trascrizione nucleare nf-kb.
FR2862659B1 (fr) 2003-11-21 2006-02-10 Pasteur Institut Genome de legionella pneumophila souche paris- applications diagnostiques et epidemiologiques
WO2005077403A1 (en) 2004-02-04 2005-08-25 Stryker Corporation Therapeutic methods using smads
JP5650367B2 (ja) 2004-02-27 2015-01-07 アンティセンス ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物
WO2005098041A2 (en) 2004-03-26 2005-10-20 University Of Florida Research Foundation, Inc. Detection and treatment of fibrotic disorders
WO2007022642A2 (en) 2005-08-25 2007-03-01 Replicor Inc. Anti-inflammatory molecules and their uses
US20080032943A1 (en) 2005-11-04 2008-02-07 Johji Inazawa Method for detecting cancer and a method for suppressing cancer
WO2007099345A1 (en) 2006-03-02 2007-09-07 Betagenon Ab Medical use of bmp-2 and/ or bmp-4
US8969295B2 (en) 2006-04-14 2015-03-03 Massachusetts Institute Of Technology Identifying and modulating molecular pathways that mediate nervous system plasticity
WO2008014400A2 (en) 2006-07-26 2008-01-31 Genizon Biosciences Inc. Crohn disease susceptibility gene
WO2008046964A2 (en) 2006-10-16 2008-04-24 Panu Jaakkola Novel useful inhibitors
US20110152352A1 (en) 2008-06-10 2011-06-23 Tufts University Smad proteins control drosha-mediated mirna maturation
AU2009315898B2 (en) 2008-11-13 2015-07-23 Nogra Pharma Limited Antisense compositions and methods of making and using same
US8110355B2 (en) 2009-02-20 2012-02-07 GenRemedy, LLC Methods for identifying agents that inhibit cell migration, promote cell adhesion and prevent metastasis
ES2617200T3 (es) 2011-09-15 2017-06-15 Nogra Pharma Limited Procedimientos para supervisar la capacidad de respuesta al tratamiento anti-SMAD7
CA2870547A1 (en) 2012-04-18 2013-10-24 Nogra Pharma Limited Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
ES2673209T3 (es) 2013-03-15 2018-06-20 Nogra Pharma Limited Procedimientos de tratamiento del cáncer colorrectal
WO2015169966A2 (en) 2014-05-09 2015-11-12 Nogra Pharma Limited Methods for treating inflammatory bowel disease
WO2016059239A1 (en) 2014-10-17 2016-04-21 Nogra Pharma Limited Methods and compositions for treating a subject with a smad7 antisense oligonucleotide
JP2017537973A (ja) 2014-10-17 2017-12-21 ノグラ ファーマ リミテッド バイオマーカーレベルを使用してｓｍａｄ７アンチセンスオリゴヌクレオチドを投与するおよびモニタリングするための方法
JP2018531936A (ja) 2015-09-30 2018-11-01 ノグラ ファーマ リミテッド バイオマーカー発現に基づいてｓｍａｄ７アンチセンスオリゴヌクレオチドを使用する方法
CA3014383A1 (en) 2016-02-24 2017-08-31 Nogra Pharma Limited Methods of treating celiac disease using smad7 inhibition
JP2020503327A (ja) 2016-12-30 2020-01-30 ノグラ ファーマ リミテッド Ｓｍａｄ７アンチセンスオリゴヌクレオチドの組成物および乾癬を処置するまたは予防する方法

Also Published As

Publication number Publication date
KR20050118705A (ko) 2005-12-19
US20200325480A1 (en) 2020-10-15
CN1788086A (zh) 2006-06-14
US20140142163A1 (en) 2014-05-22
US8648186B2 (en) 2014-02-11
US9951334B2 (en) 2018-04-24
CA2520541A1 (en) 2004-10-14
EP1608753A1 (en) 2005-12-28
ITRM20030149A0 (it) 2003-04-02
KR100822972B1 (ko) 2008-04-17
EP1608753B1 (en) 2008-12-10
CN100556461C (zh) 2009-11-04
US20190211336A1 (en) 2019-07-11
US9382541B2 (en) 2016-07-05
SI1608753T1 (sl) 2009-04-30
US9518264B2 (en) 2016-12-13
CY1108870T1 (el) 2014-07-02
US9006418B2 (en) 2015-04-14
NO20054861L (no) 2005-10-20
JP5039172B2 (ja) 2012-10-03
US20170253880A1 (en) 2017-09-07
ES2316970T3 (es) 2009-04-16
WO2004087920A1 (en) 2004-10-14
US8907078B2 (en) 2014-12-09
JP2006521815A (ja) 2006-09-28
US9096854B1 (en) 2015-08-04
US20150211011A1 (en) 2015-07-30
US20200181622A1 (en) 2020-06-11
RU2005133711A (ru) 2006-05-10
US20150218561A1 (en) 2015-08-06
JP2010193906A (ja) 2010-09-09
US8106182B2 (en) 2012-01-31
MXPA05010549A (es) 2006-05-25
US20140256788A1 (en) 2014-09-11
ATE417102T1 (de) 2008-12-15
US20100317719A1 (en) 2010-12-16
PT1608753E (pt) 2009-02-16
PL1608753T3 (pl) 2009-06-30
US20160177306A1 (en) 2016-06-23
DE602004018288D1 (de) 2009-01-22
US10633660B2 (en) 2020-04-28
JP4559411B2 (ja) 2010-10-06
US7700757B2 (en) 2010-04-20
AU2004225666B2 (en) 2008-07-10
AU2004225666A2 (en) 2004-10-14
US20130203839A1 (en) 2013-08-08
US9605264B2 (en) 2017-03-28
US20120136043A1 (en) 2012-05-31
US7807818B2 (en) 2010-10-05
US10036022B2 (en) 2018-07-31
US20150337312A1 (en) 2015-11-26
NZ542718A (en) 2007-04-27
US10738309B2 (en) 2020-08-11
US20070167385A1 (en) 2007-07-19
US20090156539A1 (en) 2009-06-18
ITRM20030149A1 (it) 2004-10-03
NO334022B1 (no) 2013-11-18
US9279126B2 (en) 2016-03-08
CA2520541C (en) 2012-05-08
US20160304876A1 (en) 2016-10-20
RU2339697C2 (ru) 2008-11-27
AU2004225666A1 (en) 2004-10-14
US20180030450A1 (en) 2018-02-01
US20070042985A1 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
DK1608753T3 (da) Antisens-oligonukleotider (ODN) mod Smad7 og anvendelser deraf i det medicinske felt
IT1306716B1 (it) Associazione di batteri lattici e suo uso per la prevenzione e/o iltrattamento terapeutico di infezioni e di stati infiammatori.
ATE393221T1 (de) Gegen bakterielle 16s und 23s rrnas gerichtete ungeladene antisense oligonukleotide und deren verwendungen
MX2009006310A (es) Composiciones y metodos para tratar trastornos musculares y cardiovasculares.
ITMI20041550A1 (it) Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell'epidermide
DE50214266D1 (de) Verfahren zur hemmung der expression eines zielgens und medikament zur therapie einer tumorerkrankung
BR0303093A (pt) Barras de limpeza contendo elementos discretos
HUP0402543A2 (hu) Bispecifikus antiszensz oligonukleotidok, amelyek IGFBP-2-t és IGFBP-5-öt gátolnak, és eljárások azok alkalmazására
DK1334194T3 (da) Afbildning, diagnosticering og behandling af sygdom
RU2008125041A (ru) миРНК ПРОТИВ МИОЗИНА VA И ДЕПИГМЕНТАЦИЯ КОЖИ
NO20052956L (no) Defensinprotiner
FI20011664A0 (fi) Syöpäpesifiset oligoskkaridisekvenssit ja niiden käyttö
ES2193958T3 (es) Inmunoadsorbentes para el tratamiento de la septicemia.
FR2886850B1 (fr) Composition a base d'une avermectine et de peroxyde de benzoyle notamment pour le traitement de la rosacee
SE0302304D0 (sv) Novel compounds
NO20053903L (no) Nukleotidlipidesterderivater.
DK1075523T3 (da) Strukturelle proteiner hos fiskepankreassygdomsvirus og anvendelser deraf
IL169256A0 (en) Metalloprotease proteins
FR2804127B1 (fr) Gene srn1 implique dans le syndrome nephrotique cortico- resistant, proteine codee par ce gene et utilisations diagnostiques et therapeutiques
TNSN06147A1 (en) Use of cathepsin k inhibitors for treating of severe bone loss diseases
EA202192330A1 (ru) Олигонуклеотиды, препятствующие экспрессии белка, ассоциированного с синдромом ломкой х-хромосомы, и способы их применения
GB0423126D0 (en) Protein
DK1159426T3 (da) Kloning og udtryk af Haemophilus somnus transferrin-bindende proteiner
BR0211533A (pt) Tratamento de dor crÈnica com 3-heterociclil- e 3-cicloalquil-3-ariloxipropanaminas
SE0202608D0 (sv) New sequences